APA (7th ed.) Citation

Lyu, H., Ishimura, A., Suzuki, R., Buyanbat, K., Batbayar, G., Meguro-Horike, M., . . . Suzuki, T. HDAC5, an early osimertinib-responsive gene, is a novel therapeutic target for the drug resistance in EGFR-mutant lung adenocarcinoma cells. Elsevier.

Chicago Style (17th ed.) Citation

Lyu, Hanbing, Akihiko Ishimura, Ryusuke Suzuki, Khurelsukh Buyanbat, Gerelsuren Batbayar, Makiko Meguro-Horike, Shin-ichi Horike, Seiji Yano, and Takeshi Suzuki. HDAC5, an Early Osimertinib-responsive Gene, Is a Novel Therapeutic Target for the Drug Resistance in EGFR-mutant Lung Adenocarcinoma Cells. Elsevier.

MLA (9th ed.) Citation

Lyu, Hanbing, et al. HDAC5, an Early Osimertinib-responsive Gene, Is a Novel Therapeutic Target for the Drug Resistance in EGFR-mutant Lung Adenocarcinoma Cells. Elsevier.